Combination Therapy for Use in Treating Retroviral Infections
AssigneeCipla Limited
InventorsGeena MALHOTRA, Kalpana JOSHI, Preeti RAUT
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition is provided comprising coy combination of antiretroviral drugs optionally in combination of pharmacokinetic boosters. The formulation is used for the treatment of diseases caused by retroviruses. The process of preparation of the formulation is also provided.
Claims23
A pharmaceutical composition comprising a therapeutically effective amount of at least one non-nucleoside reverse transcriptase inhibitor, at least one nucleoside reverse transcriptase inhibitor and at least one nucleotide reverse transcriptase inhibitor and optionally one or more pharmaceutically acceptable excipients.
A pharmaceutical composition comprising doravirine, tenofovir alafenamide, emtricitabine, piperine and optionally pharmaceutically acceptable excipients.
A method of treating diseases caused by retroviruses in a patient in need of such treatment, the method comprising:
- administering a pharmaceutical composition comprising (i) at least one nucleoside reverse transcriptase inhibitor, at least one nucleotide reverse transcriptase inhibitor and at least one non-nucleoside reverse transcriptase inhibitor;
- (ii) a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof;
- and (iii) one or more pharmaceutically acceptable excipients comprising carriers, diluents, fillers, binders, lubricants, glidants, disintegrants, bulking agents, flavourants or any combination thereof.
A kit for treating disease caused by retroviruses, the kit comprising a therapeutically effective amount of at least one non-nucleoside reverse transcriptase inhibitor, at least one nucleoside reverse transcriptase inhibitor and at least one nucleotide reverse transcriptase inhibitor wherein the at least one non-nucleoside reverse transcriptase inhibitor, at least one nucleoside reverse transcriptase inhibitor and at least one nucleotide reverse transcriptase inhibitor are in a separate composition.
A kit for treating disease caused by retroviruses, the kit comprising a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof, wherein the at least one anti-retroviral drug is in a separate composition from the at least one pharmacokinetic booster or enhancer or derivative thereof.
A method of enhancing the bioavailability of an oral anti-retroviral drug, the method comprising providing a therapeutically effective amount of at least one anti-retroviral drug and providing a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof.
Dependencies are inferred from the claim text.